Lilly and Baxter accused of fixing insulin prices in Mexico
This article was originally published in Scrip
Executive Summary
Mexico's antitrust commission, the Comisi�n Federal de Competencia (CFC), has said that Lilly, Baxter and several local firms colluded to fix the prices of their diabetes drugs. It plans to fine them Ps21.5 million ($1.7 million) each, the maximum penalty, although the firms deny any wrong doing.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.